^
Association details:
| Biomarker: | RET M918T |
|---|---|
| Cancer: | Thyroid Gland Medullary Carcinoma |
| Drug: | Caprelsa (vandetanib) (Multi-tyrosine kinase inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Four cases of medullary thyroid carcinomas associated with multiple endocrine neoplasia 2B with rearranged during transfection codon M918T mutation in the same family
Published date:
11/21/2021
Excerpt:
Case 1 included a 19 year-old male diagnosed with MTC with lung metastases. Genetic testing revealed an RET codon M918T mutation....The patient responded partially to vandetanib and the disease has shown no progression in 25 months.
DOI:
10.3892/mco.2021.2450
Source:
Title:
Safety and activity of vandetanib in combination with everolimus in patients with advanced solid tumors: a phase I study
Published date:
03/12/2021
Excerpt:
Patients were enrolled at five dose levels using 100 mg of VAN orally daily and 2.5 mg of EV orally daily for 28 days as starting doses…A patient with MTC harboring the RET M918T mutation was started on therapy...Tumor molecular profile of patient with RET M918T mutant MTC and SD as best response to VAN plus EV.
Secondary therapy:
everolimus
DOI:
10.1016/j.esmoop.2021.100079
Source:
Title:
RET Aberrations in Diverse Cancers: Next-Generation Sequencing of 4,871 Patients
Excerpt:
...the second patient was a 35-year-old man with sporadic medullary thyroid carcinoma and a RET M918T mutation as well as ATM L804fs*4 and ATM S978fs*12 alterations. Additional tumor evaluation with an IHC panel also showed strong positivity of phospho-AKT. The patient was initially treated with single-agent vandetanib with prolonged stable disease; however, the addition of everolimus led to significant tumor shrinkage.
DOI:
10.1158/1078-0432.CCR-16-1679
Trial ID:
